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Introduction: Non-clinical seizure liability studies typically aim to: 1) conﬁrm the nature of EEG activity during
abnormal clinical signs, 2) identify premonitory clinical signs, 3) measure plasma levels at seizure onset, 4)
demonstrate that drug-induced seizures are self-limiting, 5) conﬁrm that conventional drugs (e.g. diazepam)
can treat drug-induced seizures and 6) conﬁrm the no observed adverse effect level (NOAEL) at EEG. Our aim
was to originally characterize several of these items in a three species comparative study.
Methods: Cynomolgus monkey, Beagle dog and Sprague–Dawley rat with EEG telemetry transmitters were used
to obtain EEG using the 10–20 system. Pentylenetetrazol (PTZ) was used to determine seizure threshold or as a
positive seizurogenic agent. Clinical signs were recorded and premonitory signswere evaluated. In complement,
other pharmacological agents were used to illustrate various safety testing strategies.
Results: Intravenous PTZ doses required to induce clonic convulsions were 36.1 (3.8), 56.1 (12.7) and 49.4
(11.7) mg/kg, in Beagle dogs, cynomolgus monkeys and Sprague–Dawley rats, respectively. Premonitory
clinical signs typically included decreased physical activity, enhanced physiological tremors, hypersalivation,
ataxia, emesis (except in rats) and myoclonus. In Sprague–Dawley rats, amphetamine (PO) increased high
(approximately 40–120 Hz), and decreased low (1–14 Hz) frequencies. In cynomolgus monkeys, caffeine (IM)
increased power in high (14–127Hz), and attenuated power in low (1–13Hz) frequencies. In the rat PTZ infusion
seizure thresholdmodel, yohimbine (SC and IV) and phenobarbital (IP) conﬁrmed to be reliable positive controls
as pro- and anticonvulsants, respectively.
Discussion: Telemetry video-EEG for seizure liability investigations was characterized in three species. Rats
represent a ﬁrst-line model in seizure liability assessments. Beagle dogs are often associated with overt
susceptibility to seizure and are typically used in seizure liability studies only if required by regulators.
Non-human primates represent an important model in seizure liability assessments given similarities to
humans and a high translational potential.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Convulsions observed in pre-clinical studies are often the ﬁrst
indication of the seizure potential of a compound in development. In
this context, recognition of seizure activity and any premonitory signs
thereof (Scaramelli et al., 2009) obtained bymeans of a reliable method
can be crucial, as an estimated 6.1% of new-onset seizures are drug-
related (Pesola & Avasarala, 2002). Seizure detection is also of increas-
ing importance, due to the multitude of commercially available drugs
known to lower seizure threshold and/or increase the incidence of
seizures in patients taking these agents. Several widely used antibiotics,.
. This is an open access article underincluding imipenem (Miller, Ball, Bookstaver, Dornblaser, & Bennett,
2011), penicillins (Barrons, Murray, & Richey, 1992), cephalosporins
(Chow, Szeto, Hui, Wong, & Li, 2003), and some analgesics, including
tramadol (Labate, Newton, Vernon,& Berkovic, 2005) have seizurogenic
potential; Bupropion, an approved anti-depressive agent (Pesola &
Avasarala, 2002), as well as the bronchodilator aminophylline have
the potential to lower seizure threshold (Schwartz & Scott, 1974;
Yarnell & Chu, 1975); Diphenhydramine, one of the most frequently
used over-the-counter anti-histaminic drugs, is also associated with in-
creased seizure occurrence in patients (Thundiyil, Kearney, & Olson,
2007).Minaprinewaswithdrawn from themarket due to seizure liabil-
ities (Fung et al., 2001). Globally, seizures represent one of themost fre-
quent causes of injury or death in human clinical trials (Bass, Kinter, &
Williams, 2004).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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studies and clinical trials to assess adverse drug effects on the central ner-
vous system (CNS), including detection of seizure activity (Authier et al.,
2009; Leiser, Dunlop, Bowlby, & Devilbiss, 2011). Although convulsions,
deﬁned as involuntary contractions of voluntary muscles, can typically
be identiﬁed by clinical observation, conﬁrmation of seizure activity,
which by deﬁnition is due to abnormal brain electrophysiological activity,
requires the reviewof EEG.Morphological characteristics suggestive of al-
tered seizure threshold or frank seizure, including increased synchrony,
repetitive sharp waves, slow-wave complexes or spike trains, can be de-
tected by EEGmonitoring (Aiello &Mays, 1998). Sharpwaves are deﬁned
as EEG transients with a duration of 70 to 200 ms, whereas spikes have a
duration of 20 to 70 ms (Stern, 2013). In humans, EEG typically reveals
bursts of low amplitude, rhythmic and synchronized activity prior to sei-
zure onset (Niederhauser, Esteller, Echauz, Vachtsevanos, & Litt, 2003).
These observations are also considered as typical present in animals. Par-
oxysmal EEG activity, which may be premonitory to seizure (Authier
et al., 2009), is useful in neurological safety assessments (Authier et al.,
2009). When seizures are observed in non-clinical studies, characteriza-
tion of the seizure and the pharmacology surrounding the event are valu-
able to clinicians subsequently conducting clinical trials, as information
regarding the type of seizure, the timing relative to drug administration,
the maximum plasma drug concentration (Cmax), precursor clinical
signs and dose dependency will provide the clinicians with the necessary
tools to properly monitor their patients (Avila, 2011). Without EEGmon-
itoring during non-clinical studies, seizures are typically characterized
only by their overt clinical signs. Clonic convulsions are deﬁned as rapid
alternation betweenmuscular contraction and relaxation, whereas a con-
tinuous muscular contraction characterizes tonic convulsions (Blood &
Studdert, 1988). Myoclonus, occasionally referred to as myoclonic jerks,
is characterized by the involuntary jerking of amuscle or groupofmuscles
(National Institute of Neurological Disorders and Stroke, 2012a, 2012b). A
study conducted by Scaramelli et al. (2009) revealed that 39 out of 100
patients reported premonitory signs, including behavioral and cognitive
changes, prior to seizure onset. Humans may report confusion prior to a
seizure but such a qualitative sign cannot be obtained in animal models
other than by careful behavioral evaluations (e.g. disorientation, ataxia).
To support interpretation, video recording concomitant to EEG
monitoring allows for observation of premonitory signs of seizure
(e.g. salivation, emesis, ataxia, tremors) (Podell, 2010) that are not
otherwise captured by EEG recording alone. In addition, the margin
between plasma exposure at onset of premonitory clinical signs, and
at seizure onset, can bemeasured and serves to evaluate the risk associ-
ated with the drug candidate. Observation of such premonitory signs in
clinical trialswill often halt dosing. The onset of adverse effects is unpre-
dictable and restraining an animal for an extended period of time
(i.e. several hours) is not feasible or ethical. In fact, restraint has been
shown to lower seizure threshold during seizure susceptibility studies
(Swinyard, Radhakrishnan, & Goodman, 1962). Continuous video-EEG
monitoring by telemetry can be an alternative tomonitor freelymoving
animals, therefore decreasing the potential for stress-related artifacts or
changes in seizure threshold.
The current study aimed to present representative EEG results
obtained by telemetry combined with video in conscious Beagle
dogs, cynomolgus monkeys and Sprague–Dawley rats after determi-
nation of the pentylenetetrazol (PTZ)-induced seizure threshold.
Our hypothesis was that the Beagle dog would be more sensitive
to PTZ both on the seizurogenic dose and premonitory clinical signs
determination. Moreover, quantitative EEG spectral changes (qEEG)
considered as an advanced analysis strategy was undertaken in rats
and monkeys to illustrate methodologies to screen for drug-induced
stimulatory or neuro-depressive effects. Doses of non-seizurogenic
drugs used for qualiﬁcation of qEEG were selected to induce slight to
moderate effects based on historical data (unpublished). These results
are discussed in the context of seizure liability study design and
interpretation.2. Materials and methods
2.1. Statement on use and care of animals.
During the study, care and use of animals were conducted in
accordance with principles outlined in the current Guide to the
Care and Use of Experimental Animals published by the Canadian
Council on Animal Care and theGuide for the Care andUse of Laboratory
Animals published by the US National Institutes of Health (National
Research Council, 2011). CiToxLAB North America's facility is
AAALAC accredited. All procedureswere conducted as per StandardOp-
erating Procedures (SOPs) and with approval and overview of the insti-
tutional animal care and use committee.
2.2. Animal housing and preparation.
2.2.1. Beagle dog and cynomolgus monkey models
The animal room environment was controlled (temperature 21 ±
3 °C, humidity 30%–70%, 12 h light, 12 h dark, 10–15 air changes per
hour) and temperature and relative humidity were monitored continu-
ously. Five (5) Beagle dogs and twelve (12) cynomolgus monkeys were
used to generate representative datawith themodel, and their response
to the positive control drug (PTZ) (see the Experimental methods
section). At onset of treatment, Beagle dogs were 10 months old and
cynomolgus monkeys were 2 years old.
Prophylactic antibiotics (Baytril, Bayer Health Care, Toronto, ON,
Canada; 0.1 mL/kg, 50 mg/mL; Penicillin G procaine, Vetoquinol,
Lavaltrie, QC, Canada; 0.4 mL, 300 000 IU/mL) were administered by
intramuscular (IM) injection prior to surgery and daily for at least two
days. Preemptive analgesia was attained via a transdermal Fentanyl
patch (Sandoz, QC, Canada; 12.5 μg/h) over three days. An antibiotic,
Cefazolin (Novopharm, Markham, ON, Canada; 0.4 mL/kg, 80 mg/mL)
was applied to the skull surgical site. A local anesthetic (Bupivacaine,
Hospira, Montreal, QC, Canada, 0.25%, 0.5 mL; or Lidocaine, Vetoquinol,
Lavaltrie, QC, Canada; 20 mg/mL, 0.5 mL) was injected (0.1–0.2 mL) in
6–10 subcutaneous (SC) sites distributed over the skull surgical site to
ensure a multimodal analgesia. Animals were placed on a heating pad
and inhaled a mixture of oxygen (O2) and isoﬂurane (AErrane, Baxter
Corporation, Mississauga, ON, Canada). Respiratory rate was maintained
between 8 and 20 breaths/min with an inspiratory airway pressure
between 18 and 25 cm H2O using a mechanical ventilator (Hallowell
EMC, Pittsﬁeld, MA, USA). Heart rate, pulse oximetry (SpO2) and
body temperature were monitored continuously during anesthesia.
A longitudinal incision was performed lateral but close to the linea
alba, and the internal abdominal oblique muscle was separated
from the aponeurosis of the transversus abdominis. The telemetry
transmitter was placed between the internal abdominal oblique
muscle and the aponeurosis of the transversus abdominis muscle.
The rectus abdominis was sutured with a simple continuous suture
and EEG electrodes were tunneled subcutaneously to a small skin
incision in the neck. Electroencephalographic leads (TL11M2-D70-EEE,
Data Science International, St.-Paul, MN, USA) were secured on to the
skull bones to monitor three standard bipolar derivations (C3-O1, C4-O2
and Cz-Oz) using the 10–20 electrode system. A linear groove was done
in the cranial cortical bone to secure the electrodes with surgical glue
(Vetbond, 3M, St-Paul, MN, USA) and acrylic. Electromyographic (EMG)
recording was obtained using electrodes sutured to longitudinal
muscles in the neck area and recorded continuously with the telemetry
transmitter. A period of three weeks was allowed between surgery and
the start of experimental procedures.
An additional ten (10) cynomolgus monkeys (3.5–6 years old),
maintained under the same environmental conditions as described
above, were surgically prepared with the same telemetry transmitters
(TL11M2-D70-EEE, Data Science International, St.-Paul, MN, USA).
The leads were placed to monitor standard bipolar derivations (F3-C3,
C3-O1, C4-O2 and/or Cz-Oz). These animals were used for the caffeine
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qEEG spectral analysis (see below).2.2.2. Sprague–Dawley rat model
A telemetry transmitter (TL11M2-C50-PXT or F40-EET, Data Science
International, St.-Paul, MN, USA) for EEGmonitoringwas usedwith one
standard bipolar derivation (Fz-Oz) in forty nine (49) adult rats.
Animals were aged 9 to 14 weeks old. The animal room environment
was controlled (temperature 21 ± 3 °C, humidity 30%–70%, 12 h light,
12 h dark, 10–15 air changes per hour) and temperature and relative
humidity were monitored continuously.
Penicillin G procaine (Vetoquinol, Lavaltrie, QC, Canada, 1.0 mL,
300 000 IU/mL) was administered SC once daily for three days begin-
ning on the day of surgery. Buprenorphine (Champion Alstoe, Whitby,
ON, Canada, 0.04 mL, 0.3 mg/mL) was administered twice daily for
three days. Local anesthetics (Bupivacaine, Hospira, Montreal, QC,
Canada, 0.25%, 0.1 mL; Lidocaine, Vetoquinol, Lavaltrie, QC, Canada,
20 mg/mL, 0.1 mL) were injected in 4 SC sites distributed over the
skull surgical site. The animal was placed on a heating pad and inhaled
amixture of O2 and isoﬂurane. A longitudinal incisionwasperformed on
the linea alba, and a telemetry transmitterwas secured in the abdominal
cavity. Both EEGand EMGelectrodeswere tunneled subcutaneously to a
small skin incision in the neck. The abdominal skin incision was closed
with interrupted buried sutures and the animal was placed in sternal
recumbency to expose the skull for the remainder of the surgery. The
EEG leads were secured on the cranial bone to monitor one bipolar
derivation while EMG leads were sutured to longitudinal muscles of
the neck. A linear groove was done in the cranial cortical bone to secure
the electrodes with surgical glue (Vetbond, 3M, St.-Paul, MN, USA) and
acrylic. A period of three weeks was allowed between surgery and the
start of experimental procedures.
An additional twenty-four (24) Sprague–Dawley rats were used to
illustrate the qEEG response to PTZ infusion as described subsequently
in Experimental methods.2.3. Experimental methods.
2.3.1. Physiological data monitoring
Electroencephalographic data were obtained from animals using
telemetry transmitter leads using bipolar derivations (Monkey: F3-C3,
C3-O1, C4-O2 and/or Cz-Oz; Dog: Cz-Oz and C4-O2; Rat: Fz-Oz). The
EEG, and EMG, were recorded continuously from at least 24 h prior to
dosing to at least 24 h post-dosing completion (Dataquest ART, Data
Science International, St.-Paul, MN, USA). The EEGs were subjected to
computer analysis from at least one hour pre-dosing to at least 24 h
post-dosing (NeuroScore, Data Science International, St.-Paul, MN,
USA). Digital color cameras (Geovision, Irvine, CA, USA), with daylight
and infrared night vision connected to a computerized system (IBM
Intellistation Z pro, Xeon 3.8 Ghz, 3.5 TB hard drive, New Orchard
Road Armonk, NY, USA), were used for behavioral video monitoring.2.3.2. Cynomolgus monkey
Pentylenetetrazol (50 mg/mL) was administered at a dose rate of
40 mg/kg/h by intravenous (IV) infusion at a rate of 10 mL/h in twelve
(12) monkeys, until convulsion onset and the infusion was stopped
immediately. Diazepam (Sandoz, Boucherville, QC, Canada; 1.0 mg/kg)
was administered IV at seizure onset.
A caffeine challengewas conducted using a prospective, randomized,
controlled, crossover study to illustrate applications of qEEG in drug
development. Caffeine (10 mg/kg, IM)was administered approximately
10min prior to lights off to ten (10) animals (i.e. at 18:00). Sterile saline
USP was administered as a control. A wash-out of at least 3 days was
allowed between each treatment.2.3.3. Beagle dog
Pentylenetetrazol (50 mg/mL) was administered at a dose rate of
100 mg/kg/h by IV infusion toﬁve (5) dogs, until the start of convulsions
and was then stopped immediately. Diazepam (1 mg/kg, IV) was
administered immediately following seizure onset.
2.3.4. Sprague–Dawley rat
Both EEG and EMGwere recorded following saline IV infusion in rats
(n = 49) or IV PTZ infusion (cross over design with n = 8). Three
(3) rats were used to illustrate qEEG effects of diazepam (3 mg/kg, IM)
and amphetamine (3.75 mg/kg, PO).
Twenty-four (24) rats received a PTZ (8 mg/mL) IV infusion at a
dose rate of 288 mg/kg/h. Diazepam (2–6 mg/kg) was administered
by intra-peritoneal (IP) injection following tonic convulsion onset.
- Sixteen (16) Sprague–Dawley rats were used to illustrate the effect
of yohimbine (18 mg/kg, SC, 8 min prior to PTZ infusion) as a
positive control (n = 8) in the PTZ seizure threshold model, with
an equal number of animals (n= 8) receiving either yohimbine or
saline (control).
- Eight (8) Sprague–Dawley rats received phenobarbital (n = 4,
30 mg/kg, IP) or saline (n = 4, same volume) in the same seizure
threshold model initiated 30 min after phenobarbital/saline
administration.
2.4. Electroencephalographic analysis methods.
The EEG and EMG (when applicable) traces were analyzed using
manual and automated detection (NeuroScore, Data Science Interna-
tional, St.-Paul, MN, USA). Spectral analysis was performed on 60-s
epochs to quantify the absolute and relative amplitude of EEG frequency
bands (delta [0.5–4 Hz], theta [4–8 Hz], alpha [8–12 Hz], sigma [12–16 Hz],
beta [16–24 Hz] and gamma [24–50 Hz]) and individual frequencies
[0.5–127 Hz].
2.5. Statistical analysis.
For each parameter, a one-way analysis-of-variance (ANOVA) was
conducted and the residuals were saved. Gaussian distribution was
evaluated using the Shapiro–Wilk test on residuals. Whenever the
Shapiro–Wilk test was found to be signiﬁcant (p ≤ 0.001) then the
data were transformed and re-submitted to the analysis. The Levene
test was used to examine the homogeneity of group variances. For the
ANOVA model, if the overall group differences were shown signiﬁcant
(F-Test), then pair-wise comparisons were conducted using Tukey's
test. Data are presented as mean (SD).
3. Results
The EEG and EMG (when applicable) electrodes were well tolerated
in all animals.
3.1. Cynomolgus monkeys
3.1.1. Seizure assessments
Premonitory seizure signs observed during the pre-ictal period with
associated average PTZ doses are listed in Table 1. Emesis and decreased
activity were the most common clinical signs followed by hypersaliva-
tion and ataxia. Excessive vocalization, repeated yawning, excessive
scratching were also observed. Tonic and/or clonic convulsions were
noted approximately 81 min following the start of PTZ infusion and
lasted an average of 120 (83) s, corresponding to a PTZ dose of 56.1
(12.7) mg/kg. The Fig. 1A illustrates EEG ictal activity measured in the
cynomolgus monkey at the onset of seizure activity including EEG
sharp waves and spike trains. Fig. 1B demonstrates EEG activity
throughout the ictal period including post-ictal power attenuation.
Table 1
Mean (SD) PTZ doses (50 mg/mL, 40 mg/kg/h, IV) at onset of observed
premonitory signs in cynomolgus monkeys (n = 12).
Premonitory sign PTZ (mg/kg)
Emesis 28.7 (18.0)
Decreased activity 33.1 (9.8)
Hypersalivation 35.3 (16.0)
Tremors 36.7 (20.7)
Myoclonic jerks 40.5 (14.2)
Uncoordination/Ataxia 40.7 (16.1)
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ataxia were observed up to 52 min post-ictus.Fig. 2. Spectral changes in power bands prior to seizure onset in cynomolgusmonkeys PTZ
infusion (40 mg/kg/h, IV) illustrating an increase in all frequency bands except the delta
band (n= 12).3.1.2. Spectral analysis (power bands and qEEG)
Pre-ictal spectral changes compared to baseline data reveal an
increase in the higher frequency power bands (i.e. theta to beta) just
prior to and during the PTZ induced ictal period (Fig. 2) while the low
frequency delta band is not modiﬁed.
As noted in Fig. 3, spectral analysis showed changes across a large
range of frequencies (0.5–127 Hz) following caffeine administration
(10 mg/kg, IM) when compared to time-matched data obtained
following administration of saline (negative control). Decreases in
low range frequencies (0.5–13 Hz) and increases in higher frequencies
(N14–127 Hz) were observed with effects dissipating progressively
over 12 h following dosing.Fig. 1. A) EEG at seizure onset in a cynomolgusmonkey following PTZ infusion (40 mg/kg/h, IV)
cynomolgus monkey following PTZ infusion (40 mg/kg/h, IV) with characteristic post-ictal atte3.2. Beagle dogs.
3.2.1. Seizure Assessments
The Fig. 4 illustrates EEG during ictal activity in a Beagle dog following
PTZ IV infusion. Table 2 presents the averaged PTZ doses at onset of
premonitory signs including uncoordination/ataxia, excessive vocaliza-
tion and emesis noted as early as 18minprior to PTZ-induced seizure. Ad-
ditional clinical signs, such as hypersalivation, head shaking, excessiveincluding EEG sharpwaves and spike train. B). EEG activity from a representative ictus in a
nuation of power across the entire spectrum.
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min prior to convulsions. Clonic convulsions were observed at a PTZ
dose of 36.1 (3.8) mg/kg, while tonic convulsions, noted at a PTZ dose of
36.8 (5.4) mg/kg. EEG seizure activity lasted an average of 1 min 23 s as
diazepam (1.0 mg/kg) was administered immediately following the
onset of convulsions. A second dose of diazepam was administered to
75% of the animals, 95 (18) s following the ﬁrst dose, due to signs of
EEG instability or recurrence of PTZ-induced seizures. Several clinical
signs, including hypersalivation, decreased activity, ataxia, and hypersen-
sitivity were observed for up for to 25 min post-ictus.3.2.2. Spectral analysis (power bands and qEEG)
Spectral analysis revealed important changes in a large range of
frequencies (i.e. 0.5–50Hz).More speciﬁcally, when compared to values
prior to PTZ infusion, considerable increases in all power bands were
observed just prior to seizure onset (Fig. 5). During the post-ictal period,
an attenuation of high frequency power bands (sigma [12–16 Hz], beta
[16–24 Hz] and gamma [24–50 Hz]) was observed, with intermittentFig. 4. Traces of EMG and EEG during ictal activity in a represenincreases in low frequency power bands (delta [0.5–4 Hz], and theta
[4–8 Hz]). This observation is termed “postictal depression”.3.3. Sprague–Dawley rats
3.3.1. Seizure assessments
Premonitory seizure signs observed during the pre-ictal period with
associated average PTZ doses are listed in Table 3. Tremors were
observed in 75% of the animals prior to seizure. In Sprague–Dawley
rats (13 to 14 weeks of age), clonic and tonic convulsions were noted
respectively 10.3 (2.4) and 19.4 (2.8) min following the start of PTZ
infusion, corresponding to respective PTZ doses of 49.4 (11.7) and
93.3 (13.3) mg/kg. Myoclonic jerks were observed following a PTZ
dose of 43.8 (5.5) mg/kg. Fig. 6 illustrates EEG and EMG activity in a
Sprague–Dawley rat during representative repetitive sharp waves.
Phenobarbital, administered 30min prior to the start of PTZ infusion,
increased the dose required to reach tonic convulsions (Fig. 7). In con-
trast, yohimbine (SC) reduced the dose of PTZ required to elicittative Beagle dog following PTZ infusion (100 mg/kg/h, IV).
Table 2
Mean (SD) PTZ doses (50 mg/mL, 100 mg/kg/h, IV) at onset of ob-
served premonitory signs in Beagle dogs (n = 5).
Premonitory sign PTZ (mg/kg)
Excessive licking 16.7 (6.7)
Uncoordination/
Ataxia
17.4 (7.8)
Excessive vocalization 18.6 (14.5)
Emesis 21.0 (4.9)
Excessive panting 24.7 (16.6)
Retching 25.4 (10.3)
Hypersalivation 25.5 (9.9)
Chewing motion 26.3 (9.1)
Decreased activity 40.1 (2.0)
Table 3
Mean (SD) PTZdoses (8 mg/mL, 288 mg/kg/h, IV) at onset of observed pre-
monitory signs in Sprague–Dawley rats (n = 8).
Premonitory sign PTZ (mg/kg)
Chewing motion 22.5 (3.7)
Increased respiratory rate 34.0
Myoclonic jerks 44.9 (13.3)
Excessive licking 51.2
Uncoordination/Ataxia 60.1 (3.5)
Tremors 64.5 (16.9)
Decreased activity 67.9 (7.3)
235L. Bassett et al. / Journal of Pharmacological and Toxicological Methods 70 (2014) 230–240myoclonus, clonic and tonic convulsions (Fig. 8). Yohimbine given as an
IV bolus (12 mg/kg) induced spontaneous seizure in most animals
(62.5%) and signiﬁcantly reduced the PTZ threshold to paroxysmal
EEG activity and onset of clonic convulsions (p b 0.05).
3.3.2. Spectral analysis (power bands and qEEG)
Followingdiazepam(3 mg/kg), spectral analysis conﬁrmed important
increases in high frequencies (40–120 Hz) with peak increases at 73.5
(14.8) min at a frequency of 115 Hz, a phenomenon termed pharmaco-
logical dissociation. At qEEG, amphetamine (3.75 mg/kg, PO) increased
high frequencies (approximately 40–120 Hz) and decreased low
frequencies (1-14 Hz) as illustrated in Fig. 9.
4. Discussion
The human elderly population is associated with a sharp increase in
the incidence of epilepsy due to the inﬂuence of conditions such as
stroke, brain tumors, and aging-related neurodegenerative disorders
(Loiseau et al., 1990; Wallace, Shorvon, & Tallis, 1998). In parallel, the
elderly population is exposed to more prescription drugs than any
other age group. As a well-established proconvulsant agent, PTZ is
used to assess potential changes in seizurogenic threshold (Löscher,
2009). This agent is used to identify pro (anti) convulsant drugs by a
decrease (increase) in the PTZ dose required to reach seizure onset.-1200 -1000 -800 -600
Time pre-ictu
Delta (0.5-4 Hz)
Theta (4-8 Hz)
Alpha (8-12 Hz)
Sigma (12-16 Hz)
Beta (16-24 Hz)
Gamma (24-50 Hz)
Paroxysmal activity
Pa
Fig. 5. Relative pre-ictal changes in power bands from baseline following PTZ administration (
bands are noted during pre-ictal paroxysmal activity.PTZ seizurogenic threshold test represents a valuable model as part of
seizure risk assessment in drug development in all species but some
limitations also exist. A number of compounds recognized to induce
seizure act by mechanism of action which differ from PTZ. The latter is
recognized to be a noncompetitive antagonist of the γ-aminobutyric
acid (GABA)A receptor complex (Hansen, Sperling, & Sánchez, 2004;
Huang et al., 2001). In such case, the PTZ seizure threshold test may
not reﬂect the seizure risk of the drug. As a result, seizure liability testing
will typically include EEG evaluations after the drug alone as a primary
safety testing component and possibly in combination with PTZ to
assess seizure threshold. Repeated seizures may lower the seizure
threshold, a phenomenon identiﬁed as kindling,whichwasdemonstrated
with PTZ (Gilbert & Goodman, 2005). As a consequence, repeated admin-
istration of seizurogenic agents such as PTZ is discouraged in non-clinical
seizure assessments. Similarly, a non-convulsant dose administered once
may induce seizures when administered repeatedly (White, Porter, &
Kupferberg, 2008; Wilke, 2011) possibly due to drug accumulation or
delayed neurotoxicity. No single preclinical safety testing strategy can
apply to all compounds and identiﬁcation of acute or chronic drug effects
may be warranted (Ferrero et al., 2005). Designing seizure assessment
studies requires a careful evaluation of multiple facets including
pharmacology, pharmacokinetics/biodistribution, the target indication
and patient populations, regulatory requirements/expectations, species
speciﬁcity and projected clinical trial designs, to list only a few. Within
an animal species, variations in susceptibility to drug-induced seizure
need to be considered to determine the optimal group size. The incidence
of CNS adverse events in prior toxicology/pharmacology studies may-300%
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700%
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1700%
2200%
-400 -200 0
s (sec)
roxysmal activity
100 mg/kg/h, IV) in Beagle dog (time relative to seizure onset). Transient increases in all
Fig. 6. Traces of EMG and EEG during ictus in a representative Sprague–Dawley rat following PTZ infusion (288 mg/kg/h, IV), including repetitive sharp waves.
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or doses to be tested in the follow-up seizure liability study need to re-
ﬂect this anticipated incidence. Typically, group sizes of 5–10 are used
in rodents while 4–8/group is often adequate in non-rodents.
The progression of clinical signs to seizure in animals is typically
used to inform premonitory signs that are later used to halt dosing in
clinical trials. It remains that the presence and sequence of premonitory
signs in animalsmay differ from that observed in humans and caution is
recommended in the translational assumptions. When present,
discrepancies between the progression of premonitory signs in animals
compared to humans may be caused by differences in receptor binding
afﬁnity, cellular mechanisms, metabolism, biodistribution, just to name
a few. Species speciﬁcity may also impact the clinical sign proﬁle
observed prior to seizure (e.g. lack of emesis in rats, high susceptibility
to emesis in dogs). When convulsions are observed in prior non-
clinical studies, the follow-up neurological safety pharmacology study
may or not evaluate dose levels high enough to induce seizure. As the
objective of such follow-up study is to conﬁrm the no observed adverse
effect level (NOAEL) relative to seizure activity, an appropriate safety
margin (e.g. 10×) is required but dose levels considerably higher than
intended clinical dosesmay not be relevant even when such dose levels
were used in early dose range ﬁnding toxicology studies. Interactions0
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Fig. 7.Response to PTZ infusion (288 mg/kg/h, IV) inmale Sprague–Dawley rats (579±76g,
28–30 weeks old) following saline control or phenobarbital (30 mg/kg, IP) administered 30
min prior to infusion. (*p b 0.05, T-test) (n= 4 in each group).with regulators reviewing the safety data may guide in selecting the
most relevant non-clinical neurotoxicity testing strategy. When
communication with regulators is not possible, scientiﬁc justiﬁcations
(e.g. targeted indication, context of use) can be used to support design
selection.
The observation of moderate to severe tremors in a toxicology study
may trigger neurological safety concerns and understanding the nature
of those tremors presents value in completing the risk assessment.
Enhanced physiological tremors occur in healthy individuals (Sturman,
Vaillancourt, & Corcos, 2005), are usually reversible and are generally
not associated with seizure activity. Enhanced physiological tremors
may be ampliﬁed by anxiety or fear and are visible to the naked
eye (National Institute of Neurological Disorders and Stroke, 2012a,
2012b). Essential tremors occur during voluntary muscle contractions
and may also be triggered by stress or fear or by drugs including
neuroleptics, cyclosporines, and β2 adrenergic agonists (Crawford
& Zimmerman, 2011; van Harten, Hoek, Matroos, Koeter, & Kahn,
1998). Essential tremors may be associated with a mild dysfunction
of the cerebellum (Bhidayasiri, 2005). Intention tremors occur during
directed movement, result from a dysfunction of the cerebellum
(Bhidayasiri, 2005) and can be caused by trauma, tumor, stroke,
infection but also toxicity. Antiarrythmic agents, benzodiazepines0
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& Zimmerman, 2011). In drug development, an expert neurologist
is typically not present in the animal room to evaluate tremors at
the time of occurrence. In this context, synchronized high-
resolution video-EEG may be useful to investigate the potential cor-
relation between tremors and abnormal EEG activity but also to de-
ﬁne the nature of tremors and ﬁnally assess any safety concern.
Tremors are observed relatively commonly prior to seizure onset in
non-rodents, including dogs and non-human primates but also in
most rats as observed in the current study. While video monitoring
is generally useful, it may not capture subtle premonitory clinical
signs such as nystagmus, facial twitches or high frequency tremors
and the presence of an expert observer at selected timepoints (e.g.
around Tmax) can be valuable in some cases.
Clinical observations including ataxia, head shaking, nystagmus,
head tilt and nausea/vomiting can be signs of a drug induced vestibular
syndrome. Approved drugs such as metronidazole may elicit signs of
vestibular toxicity (Sammut, 2010). As clinical manifestations of a
vestibular syndromemay be similar to pre-ictal and ictal related clinical
signs to technical staff, EEG monitoring can serve to differentiate
seizures from drug-induced vestibular toxicity. The distinction between
these two clinical conditions (vestibular toxicity vs. seizure) has amajor
impact on risk assessment as seizures are recognized as life-threatening
adverse events and a vestibular syndrome is not.
In addition to video-EEG, toxicokinetic (TK) evaluations generally
constitute an important component of non-clinical seizure liability
testing. Doses allowed in clinical trials will initially be limited by theTable 4
Comparison of PTZ doses to reach myoclonic activity, clonic and tonic convulsions in the Beagl
Species PTZ dose (mg/kg)
1st Myoclonic jerk
Beagle dogs 28.8 (11.5)
Cynomolgus monkeys 40.5 (14.2)
Sprague–Dawley rats 43.8 (5.5)
a Clonic convulsions were treated in cynomolgus monkeys and only one animal presented thuman equivalent of the animal plasma concentrations that were
achieved at the highest safe dose. The TK investigations will aim to cap-
ture plasma levels at seizure onset, around premonitory clinical signs,
but also in the absence of abnormal EEG or clinical signs (i.e. at
NOAEL). Systemic and CNS drug exposure following oral administration
often present greater variability than parenteral routes which may
justify an increased TK schedule in seizure liability studies with this
treatment route. In large animals, a more intensive TK schedule can be
used to interpret CNS data in light of individual drug exposure levels.
In seizure liability studies conducted in rodents, inclusion of a satellite
TK group to conﬁrm drug exposure can be valuable to avoid any impact
the blood collections and/or animal restraint on EEG activity. To facili-
tate interpretation of video-EEG data, continuous IV infusion of the
test compoundmay allow calculation of the plasma drug concentration
at each critical observation (e.g. onset of premonitory signs, ﬁrst
myoclonic activity, seizure onset, etc.). The advantages of a progressive
well-controlled increase in plasma level may justify the use of an
IV dosing in seizure liability studies, even if the intended route of
administration of the compound is oral.
According to the ICH S7AGuideline (2001), “consideration should be
given to the selection of relevant animalmodels or other test systems so
that scientiﬁcally valid information can be derived”. As Beagle dogs are
known to be overly sensitive to idiopathic epilepsy (Edmonds et al.,
1979; Hoskins, 2000), described as a genetic disease in this breed
(Sargan, 2004), the use of Beagle dogs presents caveats for seizure risk
assessment in non-clinical studies. In the present study, the IV PTZ
dose inducing clonic convulsions in Beagle dogs was 36.1 (3.8) mg/kge dogs (n = 5), cynomolgus monkeys (n = 12) and Sprague–Dawley rats (n = 24).
1st Clonic convulsion 1st Tonic convulsion
36.1 (3.8) 36.8 (5.4)
56.1 (12.7) 57.3a
49.4 (11.7) 93.3 (13.3)
onic convulsions.
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in Sprague–Dawley rats. Some research Beagle dogs present idiopathic
epilepsy, where convulsions are noted in the absence of drug treatment.
The interictal short time EEG evaluations performed in dogs with con-
ﬁrmed idiopathic epilepsy was normal in more than 2/3 of the animals
andwas not considered a useful screeningmethod (Brauer et al., 2012).
In this context, pre-study EEG may not be sufﬁcient to detect a genetic
predisposition to lower drug induced seizure threshold. In another
study, EEG monitoring under anesthesia revealed high frequency and
low amplitude paroxysmal discharges in most dogs conﬁrmed to pres-
ent idiopathic epilepsy (Jaggy & Bernardini, 1998). As with other spe-
cies, considerable variability exists among individual dogs, which
further complicates the use of a breedwith documented genetic suscep-
tibility. Table 4 presents data obtained in similar conditions and sup-
ports the relatively high susceptibility of Beagle dogs to PTZ induced
myoclonus, clonic and tonic convulsions compared to cynomolgus
monkeys and Sprague–Dawley rats. In previous studies, the dose of
PTZ administered as SC boluses until convulsions in cynomolgus mon-
keys was reported to be 70 (17) mg/kg (Authier et al., 2009). Similar
to results from the current study, PTZ convulsive doses in conscious or
anesthetized Beagle dogs were reported at 34 (2) and 36 (5) mg/kg
IV, respectively (Dürmüller et al., 2007; van der Linde et al., 2011). In
Sprague–Dawley rats, PTZ at 50 mg/kg (IP) induced seizure and overt
convulsions (DeBoer & Friedrichs, 2009). Similar to our results, the
PTZ threshold for clonic convulsions with IV infusion in Sprague–
Dawley rats was 59 (3) mg/kg (Mirski, Rossell, McPherson, &
Traystman, 1994). In contrast, the convulsion threshold dose in adult
(8 weeks) Wistar–Unilever was reported to be much lower at 21.3 ±
2.6 mg/kg (Himmel, 2008) suggesting differences between rat strains.
The murine PTZ threshold model is usually associated with higher
doses to induce clonic (70 mg/kg) and tonic (130 mg/kg) convulsions
(CD-1 mice; Mandhane, Aavula, & Rajamannar, 2007). Cynomolgus
monkeys are used as a large animal species as they lack the genetic
predisposition to seizure aforementioned but also present genetic poly-
morphism closer to the human population (Higasino et al., 2009;
Watanabe et al., 2007). Cynomolgus monkeys may be useful to identify
seizure potential of some pharmaceutical candidates when rats failed
to identify seizure activity (Markgraf, DeBoer, & Cirino, 2010) making
the non-human primate a valuable model in some circumstances. In
comparison to the non-human primate, whose prefrontal cortex layers
are well-deﬁned (Fuster, 2008) the cytoarchitechture of the dog
prefrontal cortex appears more primitive, partly due to the vague
separation between the prefrontal and motor cortexes (Kosmal,
Stepniewska, & Markow, 1983). The growth of the prefrontal cortex
and granularization of layer IV (internal granular layer) are characteristic
in non-human primates as well as in humans (Fuster, 2008). While few
double bouquet cells are present in carnivores compared to primates (10
vs hundreds in a ~25 mm histological section), these cells, which are y-
aminobutyric acid (GABA) containing interneurons, are completely ab-
sent in rodents (Yáñez et al., 2005). In addition, there are a greater num-
ber of GABAergic neurons in the non-human primate and human in
comparison to the rat (Yáñez et al., 2005). Finally, as in the human neo-
cortex, there are hundreds of inhibitory networks established from each
double bouquet cell in the non-human primate (Yáñez et al., 2005).
When further considering species selection, the argument that the
most sensitive species should be preferred in safety assessments may
be rejected when seizures are noted in Beagle dogs on the basis of the
poor translational potential of this species and the risk of discontinuing
development of a drug candidate that would otherwise be shown as
safe at doses that are clinically effective in humans. It remains that situ-
ations where humans are more sensitive than the Beagle dog to drug-
induced seizure were reported (unpublished personal communications)
and selection of the test species should be done carefully and in conjunc-
tion with regulators, when possible.
Whenever the clinical risk of drug-induced seizure is considered
important or insufﬁciently characterized, video-EEG may be requiredin subsequent clinical trial(s) with a major impact on costs. In this con-
text, non-clinical seizure liability studiesmay reduce overall drug devel-
opment costs and ensure that drugs are advanced in the clinic at doses
demonstrated to be safe in relevant models.
From a clinical perspective, conﬁrmation that drug-induced seizures
are self-limiting and that conventional anti-convulsive drugs (e.g.
diazepam, phenytoin or propofol) can successfully treat drug-induced
seizure can be of importance. Low safety margins between the antici-
pated efﬁcacious plasma concentration and plasma levels that have
induced seizure in some animals further increase the relevance of
emergency seizure treatment conﬁrmation.
Interpretation of video-EEG data will typically be undertaken using
automated detection of seizure activity (Authier et al., 2009; White
et al., 2006) combined with manual and qualitative review of EEG by
an expert. When using automated tools, a preference is given for high
sensitivity over speciﬁcity to minimize the incidence of false negative
events. False positive activity can be classiﬁed duringmanual qualitative
review of EEG. Interrater agreement is recognized to be high for cases
with frank seizures as observed with epilepsy (Benbadis et al., 2009).
Several features of EEG traces facilitate identiﬁcation of generalized
seizure events including postictal depression characterized by an increase
in slow low voltage activities (Kaufman, 2006). It remains that inter-
observer discrepancies in EEG interpretation are reported (Walczak,
Radtke, & Lewis, 1992) especially for more subtle changes suggestive
of altered seizure threshold. This highlights the importance of using
baseline/pre-drug and time-matched EEG data as a reference for each
individual during interpretation of post-dosing EEG traces. Abnormal EEG
traces are often associated with behavioral manifestations. Consequently,
qualitative EEG review at times when selected behavioral changes
(e.g. tremors, myoclonus, ataxia, asymmetric posture, facial twitches,
stupor, etc.) were noted is common as part of data interpretation. In
some cases, telemetry implantation for EEG monitoring may interfere
with the primary scientiﬁc endpoints as would be the case in general
toxicology studieswhere histopathology is performed on an exhaustive
list of organs. Surgical implantation of a telemetry transmitter may
induce histopathological changes and is typically avoided in general
toxicology. Surface EEG monitoring at selected timepoints for 10–
30 min at each occasion based on available pharmacology data
represents an alternative strategy to investigate seizure liabilities in
toxicology studies. When using surface EEG electrodes, the addition of
EEG monitoring immediately upon identiﬁcation of selected abnormal
clinical signs may increase sensitivity of the safety assessments.
While the primary objective of video-EEGmonitoring can be seizure
liability testing, thismodel can be used to quantify neuro-stimulatory or
neuro-depressive effects of drugs on brain activity simultaneously. As
illustrated following caffeine in the cynomolgus monkey (Fig. 3) and
amphetamine and diazepam in the Sprague–Dawley rat (Fig. 9), qEEG
can be used to detect pharmacological neuromodulation. Moreover, we
observed an increase in both beta and gamma power bands following
administration of diazepam in rats despite its sedative properties (Van
Lier, Drinkenburg, van Eeten, & Coenen, 2004), a phenomenon well
characterizedwith this drug and known as pharmacological dissociation
(Jongsma, van Rijn, van Egmond, van Schaijk, & Coenen, 2000). Using the
percent change in power from a time matched period with vehicle/
control dosing in the same animals can allow for a rapid and sensitive
screening of potential neuropharmacological effects on qEEG. Analysis
over the entire spectrum of individual EEG frequencies (e.g. 1 Hz
increments from 1 to 130 Hz) allows for ﬁner assessment in pharmaco-
logical trends (Figs. 3 and 9) than would be achieved with power bands
only. When qEEG becomes of importance in a study, appropriate designs
would typically include a cross-over administration. In addition, animals
receiving different doses including control should be housed in different
rooms or scheduled for dosing on different days to avoid “across-
the-room” qEEG interferences from excitation or sedation. As one
would expect, animals receiving a dose of neuro-stimulant will
cause an increase in qEEG values from neighbor animals receiving
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administration(s) of each treatment (drug levels and control) after an
appropriate wash-out to conﬁrm reproducibility, increase sensitivity
and enhance interpretation through discrimination of individual
patterns of change.
It remains that the sensitivity of EEG monitoring is not absolute.
Brain activity obtained from electrodes placed at the skull surface
reﬂects the summation of complex neuronal activity in the multiple
layers of the cortex and other brain structures (Smith, 2005). Seizure
activity may not always be represented on EEG tracings. Approximately
10% of patients with epilepsy were reported not to show EEG depolariza-
tion (Smith, 2005). Despites potential limitations, continuous video-EEG
with EMGmonitoring is considered to be a useful tool to evaluate seizure
liabilities and neuromodulatory effects in various species during drug
development.
Conﬂicts of interest
None of the authors have any conﬂicts of interest, other than their
employment in contract research organizations.
References
Aiello, S. E., & Mays, A. (1998). The Merck veterinary manual. (8th ed.). Whitehouse
Station, NJ: Merck & Co., Inc.
Authier, S., Paquette, D., Gauvin, D., Sammut, V., Fournier, S., Chaurand, F., et al. (2009).
Video-electroencephalography in conscious non human primate using radiotelemetry
and computerized analysis: Reﬁnement of a safety pharmacology model. Journal of
Pharmacological and Toxicological Methods, 60, 88–93.
Avila, A. (2011). Assessment of seizures from nonclinical studies and their impact on
regulatory decision. Food and Drug Administration, Center for Drug Evaluation and
Research, Division of Psychiatry Products. Presentation given at Society of Toxicology
annual meeting, Washington, D.C., March 9, 2011.
Barrons, R. W., Murray, K. M., & Richey, R. M. (1992). Populations at risk for penicillin-
induced seizures. The Annals of Pharmacotherapy, 26, 26–29.
Bass, A., Kinter, L., & Williams, P. (2004). Origins, practices and future of safety
pharmacology. Journal of Pharmacological and Toxicological Methods, 49,
145–151.
Benbadis, S. R., LaFrance, W. C. Jr, Papandonatos, G. D., Korabathina, K., Lin, K., Kraemer, H.
C., et al. (2009). Interrater reliability of EEG-video monitoring. Neurology, 73(11),
843–846 (15).
Bhidayasiri, R. (2005). Differential diagnosis of common tremor syndromes. Postgraduate
Medical Journal, 81, 756–762.
Blood,D. C., & Studdert, V. P. (1988). Bailliere's comprehensive veterinary dictionary.Toronto,
ON: Bailliere Tindall.
Brauer, C., Kästner, S. B., Rohn, K., Schenk, H. C., Tünsmeyer, J., & Tipold, A. (2012). Electro-
encephalographic recordings in dogs suffering from idiopathic and symptomatic
epilepsy: Diagnostic value of interictal short time EEG protocols supplemented by
two activation techniques. Veterinary Journal, 193(1), 185–192.
Chow, K. M., Szeto, C. C., Hui, A.C., Wong, T. Y., & Li, P. K. (2003). Retrospective review of
neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy, 23, 369–373.
Crawford, P., & Zimmerman, E. E. (2011). Differentiation and diagnosis of tremor.
American Family Physician, 83(6), 697–702 (5).
DeBoer, E., & Friedrichs, G. (2009). EEG telemetry models in the rodent and non-human
primate. Journal of Pharmacological and Toxicological Methods, 60(2), 217.
Dürmüller, N., Guillaume, P., Lacroix, P., Porsolt, R. D., & Moser, P. (2007). The use of the
dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant
risk. Journal of Pharmacological and Toxicological Methods, 56(2), 234–238.
Edmonds, H. L., Jr., Hegreberg, G. A., vanGelder, N. M., Sylvester, D.M., Clemmons, R. M., &
Chatburn, C. G. (1979). Spontaneous convulsions in beagle dogs. Federation
Proceedings, 38, 2424–2428.
Ferrero, A. J., Cereseto, M., Reines, A., Bonavita, C. D., Sifonios, L. L., Rubio, M. C., et al. (2005).
Chronic treatment with ﬂuoxetine decreases seizure thresholdd in naïve but not in rats
exposed to the learned helplessness paradigm: Correlationwith the hippocampal gluta-
mate release. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 29, 678–686.
Fung, M., Thornton, A., Mybeck, K., Wu, J. H., Hornbuckle, K., & Muniz, E. (2001). Evalua-
tion of the characteristics of safety withdrawal of prescription drugs from worldwide
pharmaceutical markets—1960 to 1999. Therapeutic Innovation & Regulatory Science,
35(1), 293–317.
Fuster, J. M. (2008). The prefrontal cortex (4th ed.). San Diego, CA: Elsevier Ltd,
7–20.
Gilbert, M. E., & Goodman, J. H. (2005). Chemical Kinding. In A. Pitkanen, P. A. Schwartzkroin,
& S. L. Moshe (Eds.), Models of seizures and epilepsy (pp. 379–393). Burlington, MA:
Elsevier Academic Press.
Hansen, S. L., Sperling, B. B., & Sánchez, C. (2004). Anticonvulsant and anti-
epileptogenic effects of GABAA receptor ligands in pentylenetetrazole-kindled
mice. Progress in Neuropsychopharmacology and Biological Psychiatry, 28(1),
105–113.Higasino, A., Osada, N., Suto, Y., Hirata, M., Kameoka, Y., Takahashi, I., et al. (2009).
Development of an integrative database with 499 novel microsatellite markers
for Macaca fascicularis. BMC Genetics, 10, 24.
Himmel, H. M. (2008). Safety pharmacology assessment of central nervous system func-
tion in juvenile and adult rats: Effects of pharmacological reference compounds.
Journal of Pharmacological and Toxicological Methods, 58(2), 129–146.
Hoskins, J.D. (2000). Congenital defects of the dog. In S. J. Ettinger, & E. C. Feldman (Eds.),
Textbook of veterinary internal medicine (pp. 1983–1996) (5th ed.). Philadelphia, PA:
W.B. Saunders Company.
Huang, R. Q., Bell-Horner, C. L., Dibas, M. I., Covey, D. F., Drewe, J. A., & Dillon, G. H. (2001).
Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid
type A (GABA(A)) receptors: Mechanism and site of action. Journal of Pharmacology
& Experimental Therapeutics, 298(3), 986–995.
International Conference on Harmonisation of Technical Requirements for Registration of
Human Pharmaceuticals for Human Use. Safety Pharmacology Studies for Human
Pharmaceuticals (S7A). (2001). http://www.ich.org/ﬁleadmin/Public_Web_Site/ICH_
Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf.
Jaggy, A., & Bernardini, M. (1998). Idiopathic epilepsy in 125 dogs: A long-term study.
Clinical and electroencephalographic ﬁndings. Journal of Small Animal Practice,
39(1), 23–29.
Jongsma, M. L. A., van Rijn, C. M., van Egmond, J., van Schaijk, A., & Coenen, A.M. L. (2000).
The inﬂuence of diazepamon the electroencephalogram-evokedpotential interrelation
in rats. Neuroscience Letters, 293, 83–86.
Kaufman, D.M. (2006). Clinical neurology for psychiatrists (6th ed.). Philadelphia, PA:
Saunders Elsevier.
Kosmal, A., Stepniewska, I., & Markow, G. (1983). Laminar organization of efferent
connections of the prefrontal cortex in the dog. Acta Neurobiologiae Experimentalis,
43, 115–127.
Labate, A., Newton, M. R., Vernon, G. M., & Berkovic, S. F. (2005). Tramadol and new-onset
seizures. Medical Journal of Australia, 182, 42–43.
Leiser, S.C., Dunlop, J., Bowlby, M. R., & Devilbiss, D.M. (2011). Aligning strategies for using
EEG as a surrogate biomarker: A review of preclinical and clinical research.
Biochemical Pharmacology, 81, 1408–1421.
Loiseau, J., Loiseau, P., Duche, B., Guyot, M., Dartigues, J. F., & Aublet, B. (1990). A survey of
epileptic disorders in southwest France: Seizures in elderly patients. Annals of
Neurology, 27, 232–237.
Löscher, W. (2009). Preclinical assessment of proconvulsant drug activity and its relevance
for predicting adverse in humans. European Journal of Pharmacology, 610, 1–11.
Mandhane, S. N., Aavula, K., & Rajamannar, T. (2007). Timed pentylenetetrazol infusion
test: A comparative analysiswith s.c.PTZ andMESmodels of anticonvulsant screening
in mice. Seizure, 16(7), 636–644.
Markgraf, C. G., DeBoer, E. M., & Cirino, M. (2010). EEG in monkey but not rat
indentiﬁes seizure potential of a pharmaceutical development candidate. Journal of
Pharmacological and Toxicological Methods, 62(2), e41–e42.
Miller, A.D., Ball, A.M., Bookstaver, P. B., Dornblaser, E. K., & Bennett, C. L. (2011).
Epileptogenic potential of carbapenem agents. Pharmacotherapy, 31, 408–423.
Mirski, M.A., Rossell, L. A., McPherson, R. W., & Traystman, R. J. (1994). Dexmedetomidine
decreases seizure threshold in a rat model of experimental generalized epilepsy.
Anesthesiology, 81(6), 1422–1428.
National Institute of Neurological Disorders and Stroke (2012a). National Institutes of
Health Publication No. 12-4734. Tremor fact sheet (Retrieved November 6, 2013,
from http://www.ninds.nih.gov/disorders/tremor/detail_tremor.htm).
National Institute of Neurological Disorders and Stroke (2012b). National Institutes of
Health Publication No. 12-4793. Myoclonus fact sheet (Retrieved May 30, 2014, from
http://www.ninds.nih.gov/disorders/myoclonus/detail_myoclonus.htm).
National Research Council (2011). Guide for the Care and Use of Laboratory Animals (8th
Ed.). Washington DC: The National Academies Press.
Niederhauser, J. J., Esteller, R., Echauz, J., Vachtsevanos, G., & Litt, B. (2003). Detection
of seizure precursors from depth-EEG using a sign periodogram transform. IEEE
Transactions on Biomedical Engineering, 50, 449–458.
Pesola, G. R., & Avasarala, J. (2002). Bupropion seizure proportion among new-onset
generalized seizures and drug-related seizures presenting to an emergency department.
The Journal of Emergency Medicine, 22, 235–239.
Podell, M. (2010). Seizures. In S. J. Ettinger, & E. C. Feldman (Eds.), Textbook of
veterinary internal medicine (pp. 228–230) (7th ed.). St Louis, MI: Saunders
Elsevier.
Sammut, V. (2010). Vestibular disease. In S. J. Ettinger, & E. C. Feldman (Eds.), Textbook
of veterinary internal medicine (pp. 1446–1453) (7th ed.). St Louis, MI: Saunders
Elsevier.
Sargan, D. R. (2004). IDID: Inherited diseases in dogs: Web-based information for canine
inherited disease genetics. Mammalian Genome, 15, 503–506.
Scaramelli, A., Braga, P., Avellanal, A., Bogacz, A., Camejo, C., Rega, I., et al. (2009). Prodromal
symptoms in epileptic patients: Clinical characterization of the pre-ictal phase. Seizure:
European Journal of Epilepsy, 18, 246–250.
Schwartz, M. S., & Scott, D. F. (1974). Aminophylline-induced seizures. Epilepsia, 15,
501–505.
Smith, S. J. M. (2005). EEG in the diagnosis, classiﬁcation, and management of patients
with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 76, 2–7.
Stern, J. M. (2013). Atlas of EEG patterns (2nd ed.). Philadelphia, PA: LippincottWilliams &
Wilkins, 4–161.
Sturman, M. M., Vaillancourt, D. E., & Corcos, D.M. (2005, Jun). Effects of aging on
the regularity of physiological tremor. Journal of Neurophysiology, 93(6),
3064–3074.
Swinyard, E. A., Radhakrishnan, N., & Goodman, L. S. (1962). Effect of brief restraint on the
convulsive threshold of mice. The Journal of Pharmacology and Experimental
Therapeutics, 138, 337–342.
240 L. Bassett et al. / Journal of Pharmacological and Toxicological Methods 70 (2014) 230–240Thundiyil, J. G., Kearney, T. E., & Olson, K. R. (2007). Evolving epidemiology of drug-induced
seizures reported to a poison control center system. Journal of Medical Toxicology, 3,
15–19.
vander Linde,H. J., VanDeuren, B., Somers, Y., Teisman, A., Drinkenburg,W.H., &Gallacher, D.
J. (2011). EEG in the FEABmodel:Measurement of electroencephalographical burst sup-
pression and seizure liability in safety pharmacology. Journal of Pharmacological and
Toxicological Methods, 63, 96–101.
van Harten, P. N., Hoek, H.W., Matroos, G. E., Koeter, M., & Kahn, R. S. (1998). Intermittent
neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal
Syndromes Study III. American Journal of Psychiatry, 155(4), 565–567.
Van Lier, H., Drinkenburg, W. H., van Eeten, Y. J., & Coenen, A.M. (2004). Effects of diazepam
and zolpidemon EEGbeta frequencies are behavior-speciﬁc in rats.Neuropharmacology,
47, 163–174.
Walczak, T. S., Radtke, R. A., & Lewis, D.V. (1992). Accuracy and interobserver reliability of
scalp ictal EEG. Neurology, 42(12), 2279–2285.
Wallace, H., Shorvon, S., & Tallis, R. (1998). Age-speciﬁc incidence and prevalence rates of
treated epilepsy in an unselected population of 2,052,922 and age-speciﬁc fertility
rates of women with epilepsy. The Lancet, 352, 1970–1973.Watanabe, A., Shiina, T., Shimizu, S., Hosomichi, K., Yanagiya, K., Kita, Y. F., et al.
(2007). A BAC-based contig map of the cynomolgus macaque (Macaca fascicularis)
major histocompatibility complex genomic region. Genomics, 89, 402–412.
White, H. S., Porter, R. J., & Kupferberg, H. J. (2008). Screening of new compounds and the
role of the pharmaceutical industry. In J. J. Engel, & T. A. Pedley (Eds.), Epilepsy. A
Comprehensive Textbook (pp. 1469–1485) (2nd ed.). Philadelphia, PA: Wolters
Kluwer/Lippincott Williams & Wilkins.
White, A.M., Williams, P. A., Ferraro, D. J., Clark, S., Kadam, S. D., Dudek, F. E., et al. (2006).
Efﬁcient unsupervised algorithms for the detection of seizures in continuous EEG
recordings from rats after brain injury. Journal of Neuroscience Methods, 152(1–2),
255–266.
Wilke, A. (2011, March 9). Approaches to seizures, and industry perspective. Chorus
Resonance. Presentation given at Society of Toxicology annual meeting (Washington,
D.C.).
Yáñez, I. B., Muñoz, A., Contrepas, J., Gonzalez, J., Rodriguez-Veiga, E., & DeFelipe, J. (2005).
Double bouquet cell in the human cerebral cortex and a comparison with other
mammals. The Journal of Comparative Neurology, 486, 344–360.
Yarnell, P. R., & Chu, N. (1975). Focal seizures and aminophylline. Neurology, 25, 819–822.
